MORRIS PLAINS, N.J., June 8, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that nine presentations will be given at the 56th Annual Meeting of the Society of Nuclear Medicine (SNM), scheduled for June 13 - 17, 2009, in Toronto, Canada. The schedule and meeting places for the oral presentations and scientific poster sessions, together with the publication numbers are listed below:
* "Durable responses with (90)Y-epratuzumab fractionated radioimmunotherapy (RAIT) in NHL" (Publication No. 45, Sunday, June 14, 1:33 p.m. - 1:45 p.m., Scientific Paper Session (Oral), Session Info: Radiopharmaceutical Therapy I, Room 707) * "Pretargeted radioimmunotherapy (PT-RAIT) in progressive medullary thyroid cancer (MTC)" (Publication No. 105, Sunday, June 14, 4:15 p.m. - 5:45 p.m., Scientific Paper Session (Oral), Session Info: Nuclear Oncology Council Young Investigator Award Symposium, Room 707) * "A novel method of radiolabeling peptides with aluminum-fluoride-18 (AlF-18) using various NOTA derivatives" (Publication No. 202, Monday, June 15, 12:42 p.m. - 12:54 p.m., Scientific Paper Session (Oral), Session Info: General Applications II, Room 713B) * "Pretargeted immunoPET for imaging colorectal cancer in a mouse model" (Publication No. 381, Tuesday, June 16, 9:45 a.m. - 9:57 a.m., Scientific Paper Session (Oral), Session Info: Antibodies and Larger Molecules, Room 707) * "(18)F labeling of a peptide for PET imaging of receptor-expressing tumors" (Publication No. 1567, Tuesday, June 16, 4:30 p.m. - 5:15 p.m., Scientific Poster Session, Poster Section: Basic Science Posters, Exhibit Hall E/F) * "Pretargeted radioimmunotherapy effectively inhibits growth of subcutaneous colon carcinoma xenografts in nude mice" (Publication No. 1570, Tuesday, June 16, 4:30 p.m. - 5:15 p.m., Scientific Poster Session, Poster Section: Basic Science Posters, Exhibit Hall E/F) * "(90)Y-hPAM4 radioimmunotherapy (RAIT) plus radiosensitizing gemcitabine (GEM) in advanced pancreatic cancer (PC)" (Publication No. 1614, Tuesday, June 16, 4:30 p.m. - 5:15 p.m., Scientific Poster Session, Poster Section: Therapy Metrics and Intervention Posters, Exhibit Hall E/F) * "Fractionated pretargeted radioimmunotherapy (PT-RAIT) of pancreatic cancer xenografts" (Publication No. 1639, Tuesday, June 16, 4:30 p.m. - 5:15 p.m., Scientific Poster Session, Poster Section: Therapy Metrics and Intervention Posters, Exhibit Hall E/F) * "Combination anti-CD20 immunotherapy and pretargeted anti-CD20 radioimmunotherapy (PT-RAIT) of non-Hodgkin's lymphoma (NHL) shows improved efficacy" (Publication No. 574, Wednesday, June 17, 8:12 a.m. - 8:24 a.m., Scientific Paper Session (Oral), Session Info: Translation Nuclear Medicine, Room 707)
About Immunomedics
Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 134 patents issued in the United States and more than 300 other patents issued worldwide, protects our product candidates and technologies. For additional information on us, please visit our website at www.immunomedics.com. The information on our website does not, however, form a part of this press release.
This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.